Wall Street equity research analysts tracking Verastem Inc. maintain an overwhelmingly positive consensus rating, categorized primarily as a Buy or Strong Buy. Optimism is driven by its advancing clinical pipeline and commercial product rollouts, though clinical-stage biopharmaceutical investments inherently carry high volatility and regulatory risks. What is your specific risk tolerance and target portfolio weight for speculative biotech equities?